Holen Sie sich die Stockscreener-App
35.39
1.55%
0.54
Vorhandelsmarkt:
35.20
-0.19
-0.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$34.85
Offen:
$34.45
24-Stunden-Volumen:
1.17M
Relative Volume:
0.54
Marktkapitalisierung:
$3.17B
Einnahmen:
$333.87M
Nettoeinkommen (Verlust:
$-169.00M
KGV:
-17.35
EPS:
-2.04
Netto-Cashflow:
$-157.30M
1W Leistung:
-2.40%
1M Leistung:
+3.69%
6M Leistung:
+132.52%
1J Leistung:
+82.71%
1-Tages-Spanne:
$34.45
$35.63
1-Wochen-Bereich:
$33.45
$37.50
52-Wochen-Spanne:
$12.91
$37.50
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
35.39 | 3.12B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Capital Fund Management S.A. Acquires Shares of 101,406 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) CFO Christopher Cline Sells 20,000 Shares - MarketBeat
Panagora Asset Management Inc. Buys 96,062 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics CFO Sells 20,000 Shares - TradingView
Loomis Sayles & Co. L P Trims Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Is Carrying A Fair Bit Of Debt - 富途牛牛
Legal & General Group Plc Boosts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewir - The National Law Review
Travere Therapeutics (TVTX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Evercore Healthcare Conference - MarketScreener
The Insider Report: The Dip Was Bought Before the Holidays - Benzinga
Virtus Investment Advisers LLC Buys 9,699 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
F m Investments LLC Has $2.78 Million Stock Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Is Travere Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Verified Entry Point Signals - BỘ NỘI VỤ
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Intech Investment Management LLC Cuts Stake in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Bought by Geode Capital Management LLC - MarketBeat
SG Americas Securities LLC Purchases Shares of 31,926 Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. 2025 Q3ResultsEarnings Call Presentation (NASDAQ:TVTX) 2025-11-29 - Seeking Alpha
Travere Therapeutics stock hits 52-week high at 37.12 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics stock hits 52-week high at 37.12 USD - Investing.com
TVTX: HC Wainwright Reiterates Buy Rating and Maintains Price Ta - GuruFocus
HC Wainwright & Co. Reiterates Travere Therapeutics (TVTX) Buy Recommendation - Nasdaq
Travere Therapeutics Delivers Growth As FILSPARI Drives Profits - Finimize
A Look at Travere Therapeutics’s Valuation Following FDA Updates Boosting FILSPARI’s Accessibility and Growth Prospects - Sahm
How Travere Therapeutics Inc. stock reacts to bond yieldsWeekly Stock Recap & AI Driven Stock Movement Reports - BỘ NỘI VỤ
How Travere Therapeutics Inc. stock trades during market volatilityWeekly Stock Analysis & Safe Entry Trade Reports - BỘ NỘI VỤ
Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA (TVTX) - Seeking Alpha
American Kidney Fund Hosts Third Patient Access Initiative Summit to Address Barriers to Kidney Care and Propose Innovative Solutions - GlobeNewswire Inc.
How institutional buying supports Travere Therapeutics Inc. stockMarket Trend Summary & Daily Profit Maximizing Trade Tips - newser.com
Will Travere Therapeutics Inc. stock maintain dividend yieldWeekly Earnings Recap & Real-Time Chart Breakout Alerts - newser.com
Is Travere Therapeutics Inc. stock trading at a premium valuationWeekly Loss Report & AI Driven Price Predictions - newser.com
Is Travere Therapeutics Inc. stock in correction or buying zoneJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
(TVTX) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
What makes Travere Therapeutics Inc. stock attractive to growth funds2025 Top Decliners & Expert Approved Trade Ideas - newser.com
What indicators show strength in Travere Therapeutics Inc.July 2025 Price Swings & AI Powered Market Trend Analysis - newser.com
What momentum shifts mean for Travere Therapeutics Inc.2025 Technical Overview & Safe Capital Growth Stock Tips - newser.com
Can Travere Therapeutics Inc. stock deliver strong Q4 earningsPortfolio Risk Report & Weekly Watchlist of Top Performers - newser.com
How Travere Therapeutics Inc. stock compares to industry benchmarksQuarterly Performance Summary & Weekly Breakout Stock Alerts - newser.com
Will Travere Therapeutics Inc. stock outperform international peersTrade Risk Report & Free Expert Approved Momentum Trade Ideas - newser.com
Will Positive Phase 3 FILSPARI Data in FSGS Redefine Travere Therapeutics' (TVTX) Position in Rare Kidney Disease? - Sahm
Real time scanner hits for Travere Therapeutics Inc. explainedMarket Volume Report & Weekly High Return Stock Forecasts - newser.com
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally - AOL.com
Travere Therapeutics stock hits 52-week high at 36.81 USD By Investing.com - Investing.com Canada
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):